SOX11阴性套细胞淋巴瘤 75例患者的临床病理和预后特征


好评必备! 免费下载

  研究表明,SOX11表达对套细胞淋巴瘤(mantle cell lymphoma,MCL)患者预后有影响,但数据存在争议。本研究中,我们描述了75例SOX11阴性MCL患者的临床病理和预后特征。与SOX11阳性MCL患者相比,SOX11阴性MCL患者更常发生非淋巴结受累的白血病(21%vs.4%,P=0.0001)。SOX11阴性MCL更常表现为典型的组织学形态(83%vs65%,P=0.005),CD23(39%vs.22%,P=0.02)和CD200(60%vs.9%,P=0.0001)阳性率更高,并且具有较低的增殖指数(Ki67 23%vs.33%,P=0.04)。SOX11阴性和SOX11阳性MCL患者的总生存期(overall survival,OS)无显著差异(P=0.63)。高增殖指数和母细胞样/多形性形态与SOX11阴性和SOX11阳性MCL组的OS较短相关(P<0.05)。套细胞淋巴瘤国际预后指数(Mantle Cell Lymphoma International Prognostic Index,MIPI)高预测SOX11阴性MCL患者的预后较差(P<0.0001),而SOX11阳性MCL患者(P=0.09)并非如此。结内受累和III/IV期疾病提示SOX11阳性MCL患者预后较差(分别为P=0.03和0.04),但对SOX11阴性MCL并没有显著差异(分别为P=0.88和0.74)。总之,SOX11阴性MCL的特征是更高的非淋巴结受累的白血病发生率、经典的组织学形态、更高的CD23和CD200表达率,以及更低的Ki67指数。SOX11阴性MCL患者的预后影响因素包括组织形态学、Ki67指数和MIPI评分。
  Am J Surg Pathol 2019;43:710–716
  (倪皓 翻译 郭凌川 审校)
  The American Journal of Surgical Pathology中文版声明:
  ©2018 Wolters Kluwer Health
  The material is published by Wolters Kluwer Health with the permission of American Journal of Surgical Pathology.No part of this publication may be reproduced in any form,stored in a retrieval system or transmitted in any form,by any means,without prior written permission from Wolters Kluwer Health.Opinions expressed by the authors and advertisers are not necessarily those of the American Journal of Surgical Pathology, its affiliates,or of the Publisher.The American Journal of Surgical Pathology,its affiliates,and the Publisher disclaim any liability to any party for the accuracy,completeness,efficacy,or availability of the material contained in this publication (including drug dosages) or for any damages arising out of the use or non-use of any of the material contained in this publication.
  Although advertising material is expected to conform to ethical (medical) standards,inclusion in this publication does not constitute a guarantee or endorsement of the quality or value of such product or of the claims made of it by its manufacturer.

  【本文经《美国外科病理学杂志》授权发布,其他媒体转载或引用须经《美国外科病理学杂志》同意 ,否则追究法律责任;所有文章仅供公益交流,不代表本站立场。欢迎提供素材、资料等,投稿邮箱:,一经采纳将给予稿费】
责任编辑: zh025
0 0 0